NCT06793956

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

Open-Label, Phase Ib Study of Sintilimab and Linperlisib Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (NKTCL)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).

Conditions

• Extranodal Natural Killer/T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Sintilimab and Linperlisib Combination Treatment	Sintilimab administered via intravenous infusion; Linperlisib administered orally.

Timeline

• Start date: 2025-02-21
• Primary completion: 2026-01-31
• Completion: 2030-01-31
• First posted: 2025-01-27
• Last updated: 2025-03-13

Locations

1 site across 1 country: China